LAM-001
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
Key Facts
About OrphAI Therapeutics
OrphAI Therapeutics is a private, preclinical to Phase 2 biotech founded in 2020 and headquartered in New Haven, Connecticut. The company is advancing a focused pipeline led by LAM-001, a candidate in Phase 2 for Bronchiolitis Obliterans Syndrome (BOS) and earlier stages for pulmonary hypertension-associated disorders, alongside earlier-stage oncology and neurology programs. Utilizing an AI/ML-driven discovery platform, OrphAI aims to develop life-saving drugs for niche, underserved patient populations, operating as a pre-revenue entity with a lean, experienced leadership team.
View full company profileAbout OrphAI Therapeutics
OrphAI Therapeutics is a private, preclinical to Phase 2 biotech founded in 2020 and headquartered in New Haven, Connecticut. The company is advancing a focused pipeline led by LAM-001, a candidate in Phase 2 for Bronchiolitis Obliterans Syndrome (BOS) and earlier stages for pulmonary hypertension-associated disorders, alongside earlier-stage oncology and neurology programs. Utilizing an AI/ML-driven discovery platform, OrphAI aims to develop life-saving drugs for niche, underserved patient populations, operating as a pre-revenue entity with a lean, experienced leadership team.
View full company profileAbout OrphAI Therapeutics
OrphAI Therapeutics is a private, preclinical to Phase 2 biotech founded in 2020 and headquartered in New Haven, Connecticut. The company is advancing a focused pipeline led by LAM-001, a candidate in Phase 2 for Bronchiolitis Obliterans Syndrome (BOS) and earlier stages for pulmonary hypertension-associated disorders, alongside earlier-stage oncology and neurology programs. Utilizing an AI/ML-driven discovery platform, OrphAI aims to develop life-saving drugs for niche, underserved patient populations, operating as a pre-revenue entity with a lean, experienced leadership team.
View full company profileOther Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Drugs
| Drug | Company | Phase |
|---|---|---|
| YUTREPIA™ (treprostinil) inhalation powder | Liquidia | Approved |
| mosliciguat | Pulmovant | Phase 2 |
| TPIP (Treprostinil Palmitil Inhalation Powder) | Insmed | Phase 2a |
| Seralutinib | Gossamer Bio | Phase 3 |